Exin Therapeutics vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF AI neurotherapeutics discovery platform for epilepsy/autism/Parkinson's with multimodal neural AI; animal lab + proof-of-concept + 2 patents in 1.5 months; $25M Philippines lab investment competing with Recursion for AI-driven CNS gene therapy.
About
Exin Therapeutics is a San Francisco-based AI-powered neurotherapeutics drug discovery company — pioneering genetic therapies that target neural activity to treat epilepsy, autism spectrum disorder symptoms, Parkinson's disease, and other neurological conditions using a multimodal AI platform that predicts therapeutic candidate potential across multiple neural disorders simultaneously. Using neural activity recordings, behavioral assays, and transcriptomics data as inputs, Exin's AI models identify genetic intervention targets and predict therapeutic outcomes before entering animal studies — compressing the target identification timeline that traditional neuroscience drug discovery requires. The company established an animal research facility, obtained proof-of-concept results in mice, and filed two provisional patents within 1.5 months of San Francisco operations, and is investing approximately $25 million to build the Philippines' first neurotherapeutics laboratory.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.